$VYGR
Voyager Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015304 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $24.60M
YoY Change 433.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.168M
YoY Change -1.59%
% of Gross Profit
Research & Development $30.24M
YoY Change 16.93%
% of Gross Profit
Depreciation & Amortization $1.132M
YoY Change 25.78%
% of Gross Profit
Operating Expenses $38.41M
YoY Change 12.57%
Operating Profit -$13.78M
YoY Change -53.3%
Interest Expense $4.579M
YoY Change 33.54%
% of Operating Profit
Other Income/Expense, Net $4.779M
YoY Change 39.37%
Pretax Income -$9.001M
YoY Change -65.48%
Income Tax $43.00K
% Of Pretax Income
Net Earnings -$9.044M
YoY Change -65.08%
Net Earnings / Revenue -36.76%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 54.63M 54.53M
Diluted Shares Outstanding 57.85M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $345.4M
YoY Change 36.56%
Cash & Equivalents $112.5M
Short-Term Investments $232.8M
Other Short-Term Assets $8.415M
YoY Change 47.63%
Inventory
Prepaid Expenses
Receivables $19.67M
Other Receivables $0.00
Total Short-Term Assets $373.4M
YoY Change 42.58%
LONG-TERM ASSETS
Property, Plant & Equipment $15.20M
YoY Change -11.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.874M
YoY Change 79.63%
Total Long-Term Assets $52.60M
YoY Change 60.71%
TOTAL ASSETS
Total Short-Term Assets $373.4M
Total Long-Term Assets $52.60M
Total Assets $426.0M
YoY Change 44.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.160M
YoY Change -3.36%
Accrued Expenses $11.44M
YoY Change 3.54%
Deferred Revenue $22.63M
YoY Change -48.87%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.21M
YoY Change -28.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $39.37M
YoY Change 108.09%
Total Long-Term Liabilities $39.37M
YoY Change 108.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.21M
Total Long-Term Liabilities $39.37M
Total Liabilities $95.73M
YoY Change -19.17%
SHAREHOLDERS EQUITY
Retained Earnings -$291.7M
YoY Change -8.15%
Common Stock $55.00K
YoY Change 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $330.3M
YoY Change
Total Liabilities & Shareholders Equity $426.0M
YoY Change 44.59%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$9.044M
YoY Change -65.08%
Depreciation, Depletion And Amortization $1.132M
YoY Change 25.78%
Cash From Operating Activities -$27.97M
YoY Change 33.18%
INVESTING ACTIVITIES
Capital Expenditures $258.0K
YoY Change -67.75%
Acquisitions
YoY Change
Other Investing Activities $64.61M
YoY Change -141.02%
Cash From Investing Activities $64.35M
YoY Change -140.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.00K
YoY Change -95.33%
NET CHANGE
Cash From Operating Activities -27.97M
Cash From Investing Activities 64.35M
Cash From Financing Activities 14.00K
Net Change In Cash 36.40M
YoY Change -120.33%
FREE CASH FLOW
Cash From Operating Activities -$27.97M
Capital Expenditures $258.0K
Free Cash Flow -$28.23M
YoY Change 29.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44038333
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001640266
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54542048
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37625
dei Entity Registrant Name
EntityRegistrantName
Voyager Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3003182
dei Entity Address Address Line1
EntityAddressAddressLine1
75 Hayden Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
259-5340
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Trading Symbol
TradingSymbol
VYGR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54625586
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112525000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68802000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
232835000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
162073000
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
15954000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
80150000
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3714000
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
3341000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8415000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5318000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
373443000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
319684000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15201000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16494000
CY2024Q3 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
2874000
CY2023Q4 vygr Deposits And Other Non Current Assets
DepositsAndOtherNonCurrentAssets
1593000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34523000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
13510000
CY2024Q3 us-gaap Assets
Assets
426041000
CY2023Q4 us-gaap Assets
Assets
351281000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3160000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1604000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11442000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16823000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6979000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3200000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22629000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
42881000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44210000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64508000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
12153000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
32359000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39368000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18094000
CY2024Q3 us-gaap Liabilities
Liabilities
95731000
CY2023Q4 us-gaap Liabilities
Liabilities
114961000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54542048
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
55000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
621985000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291697000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261182000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
330310000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
426041000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351281000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24629000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4614000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73723000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30241000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25863000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54542048
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44038333
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
55000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
621985000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
497506000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291697000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261182000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
330310000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
426041000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
351281000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24629000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4614000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73723000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
159947000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30241000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25863000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91785000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66416000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8258000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26926000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25580000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
38409000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34121000
us-gaap Operating Expenses
OperatingExpenses
118711000
us-gaap Operating Expenses
OperatingExpenses
91996000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29507000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44988000
us-gaap Operating Income Loss
OperatingIncomeLoss
67951000
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4579000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3429000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14334000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8567000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
220000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4779000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3429000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14554000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8570000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9001000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26078000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30434000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
76521000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
91785000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66416000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8168000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8258000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26926000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25580000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
38409000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34121000
us-gaap Operating Expenses
OperatingExpenses
118711000
us-gaap Operating Expenses
OperatingExpenses
91996000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13780000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29507000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44988000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3429000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14334000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8567000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
220000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4779000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3429000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9001000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26078000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30434000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
76521000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
43000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-177000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
586000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9044000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-25901000
us-gaap Net Income Loss
NetIncomeLoss
-30515000
us-gaap Net Income Loss
NetIncomeLoss
75935000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
489000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
489000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-115000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-29000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8555000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26016000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
75906000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
81000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
586000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9044000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-25901000
us-gaap Net Income Loss
NetIncomeLoss
-30515000
us-gaap Net Income Loss
NetIncomeLoss
75935000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
489000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-115000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-29000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8555000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26016000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
75906000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.78
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40962116
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57851110
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43864838
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57564413
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42610724
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2504000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216961000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1229000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
418000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2627000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22208000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
199026000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
415000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2795000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-25901000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
176220000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.78
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57851110
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43864838
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57564413
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42610724
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
59020000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
185000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2504000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
124044000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216961000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1229000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2627000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-22208000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2795000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-25901000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
176220000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2024Q1 vygr Stock And Pre Funded Warrants Issued During Period Value New Issues
StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
93473000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-458000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11330000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
340886000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
90000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
639000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3959000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10141000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
335417000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000
CY2024Q3 vygr Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
1000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3355000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
489000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9044000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
330310000
us-gaap Profit Loss
ProfitLoss
-30515000
us-gaap Profit Loss
ProfitLoss
75935000
us-gaap Share Based Compensation
ShareBasedCompensation
11048000
us-gaap Depreciation
Depreciation
3106000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2776000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
236320000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
78000
CY2024Q1 vygr Stock And Pre Funded Warrants Issued During Period Value New Issues
StockAndPreFundedWarrantsIssuedDuringPeriodValueNewIssues
93473000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3498000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-458000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-11330000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
90000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
639000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
335417000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000
CY2024Q3 vygr Vesting Of Restricted Common Stock
VestingOfRestrictedCommonStock
1000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3355000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
489000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9044000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
330310000
us-gaap Profit Loss
ProfitLoss
-30515000
us-gaap Profit Loss
ProfitLoss
75935000
us-gaap Share Based Compensation
ShareBasedCompensation
11048000
us-gaap Share Based Compensation
ShareBasedCompensation
8108000
us-gaap Depreciation
Depreciation
3720000
us-gaap Depreciation
Depreciation
3106000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
2776000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6456000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1832000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-478000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-143000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-64196000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
373000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
2996000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3097000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
342000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3423000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1459000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1556000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
704000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5381000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3236000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1698000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2102000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-40458000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16260000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-781000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
101679000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3366000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2501000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
334667000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
194975000
vygr Proceeds From Sales Of Marketable Investments
ProceedsFromSalesOfMarketableInvestments
270377000
vygr Proceeds From Sales Of Marketable Investments
ProceedsFromSalesOfMarketableInvestments
29000000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
6456000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1832000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-478000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-143000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-64196000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
373000
vygr Increase Decrease In Collaboration Receivables
IncreaseDecreaseInCollaborationReceivables
2996000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3097000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
342000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-3423000
vygr Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
-1459000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1556000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
704000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5381000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3236000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1698000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2102000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-40458000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16260000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-781000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
101679000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3366000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2501000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
334667000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
194975000
vygr Proceeds From Sales Of Marketable Investments
ProceedsFromSalesOfMarketableInvestments
270377000
vygr Proceeds From Sales Of Marketable Investments
ProceedsFromSalesOfMarketableInvestments
29000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67656000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168476000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
261000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93473000
vygr Proceeds From Issuance Of Common Stock In Connection With2023 Novartis Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement
19305000
vygr Proceeds From Issuance Of Common Stock In Connection With2023 Neurocrine Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement
31121000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
402000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
235000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113441000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33185000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45004000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33612000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115399000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66862000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26751000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67656000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168476000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
261000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1829000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93473000
vygr Proceeds From Issuance Of Common Stock In Connection With2023 Novartis Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NovartisCollaborationAgreement
19305000
vygr Proceeds From Issuance Of Common Stock In Connection With2023 Neurocrine Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWith2023NeurocrineCollaborationAgreement
31121000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
402000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
235000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113441000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33185000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45004000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33612000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70395000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100474000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115399000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66862000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
26751000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE</b><b style="font-weight:bold;">S TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease; amyotrophic lateral sclerosis; Parkinson’s disease, and multiple other diseases of the central nervous system. Many of the Company’s programs are derived from its TRACER™ adeno-associated virus (“AAV”) capsid discovery platform, which the Company has used to generate novel capsids (“TRACER Capsids”) and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Company’s programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, (“Novartis”); and Neurocrine Biosciences, Inc. (“Neurocrine”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has a history of incurring annual net operating losses. As of September 30, 2024, the Company had an accumulated deficit of $291.7 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $345.4 million. Based upon the Company’s current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2024 to be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291700000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
345400000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">VOYAGER THERAPEUTICS INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE</b><b style="font-weight:bold;">S TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Voyager Therapeutics, Inc. (the “Company”) is a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease; amyotrophic lateral sclerosis; Parkinson’s disease, and multiple other diseases of the central nervous system. Many of the Company’s programs are derived from its TRACER™ adeno-associated virus (“AAV”) capsid discovery platform, which the Company has used to generate novel capsids (“TRACER Capsids”) and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of the Company’s programs are wholly-owned, and some are advancing with licensees and collaborators including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG, (“Novartis”); and Neurocrine Biosciences, Inc. (“Neurocrine”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company has a history of incurring annual net operating losses. As of September 30, 2024, the Company had an accumulated deficit of $291.7 million. The Company has not generated any product revenue and has financed its operations primarily through public offerings and private placements of its equity securities, funding from fees, option exercise payments, and milestone payments, and cost reimbursements associated with its prior and ongoing collaborations and license agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, the Company had cash, cash equivalents, and marketable securities of $345.4 million. Based upon the Company’s current operating plans, the Company expects that its existing cash, cash equivalents, and marketable securities at September 30, 2024 to be sufficient to meet the Company’s planned operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">There can be no assurance that the Company will be able to obtain additional debt or equity financing on terms acceptable to the Company or generate product revenue or revenue from collaboration partners, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition. </p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291700000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
345400000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:10.0pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, estimates related to revenue recognition, incremental borrowing rate for leases, accrued expenses, stock-based compensation expense, and income taxes. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</p>
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
158000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2024Q3 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
339326000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2023Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
227663000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44200000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112525000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68802000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
2874000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1593000
CY2024Q3 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
339232000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
158000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
64000
CY2024Q3 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
339326000
CY2023Q4 vygr Money Market Funds And Marketable Securities Amortized Cost Basis
MoneyMarketFundsAndMarketableSecuritiesAmortizedCostBasis
227583000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
93000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2023Q4 vygr Money Market Funds And Marketable Securities Fair Value
MoneyMarketFundsAndMarketableSecuritiesFairValue
227663000
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
96000000.0
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
44200000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112525000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68802000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
2874000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1593000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115399000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70395000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5927000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6614000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115399000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70395000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5927000
CY2024Q3 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3972000
CY2023Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5225000
CY2024Q3 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
530000
CY2023Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
4229000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1013000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
755000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11442000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16823000
us-gaap Sublease Income
SubleaseIncome
200000
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
200000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
8000000.0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2024Q3 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3972000
CY2023Q4 vygr Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5225000
CY2024Q3 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
530000
CY2023Q4 vygr Accrued Goods And Services Current
AccruedGoodsAndServicesCurrent
4229000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1013000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
755000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11442000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16823000
us-gaap Sublease Income
SubleaseIncome
200000
CY2024Q3 us-gaap Sublease Income
SubleaseIncome
200000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
8000000.0
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
900000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y10M24D
CY2024Q3 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.068
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6979000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3200000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6979000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3200000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38368000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17093000
CY2024Q3 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1000000
CY2023Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39368000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18094000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24600000
CY2024Q3 vygr Operating Lease Weighted Average Incremental Borrowing Rate
OperatingLeaseWeightedAverageIncrementalBorrowingRate
0.068
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6979000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3200000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6979000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3200000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38368000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17093000
CY2024Q3 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1000000
CY2023Q4 vygr Miscellaneous Other Liabilities Noncurrent
MiscellaneousOtherLiabilitiesNoncurrent
1001000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39368000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18094000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24600000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
159900000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2878000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11048000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8108000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2878000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4600000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73700000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
159900000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8108000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2878000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11048000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8108000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11048000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8108000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7425444
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2325226
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.79
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
86100
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
793242
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.69
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8871328
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3756000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4604321
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2777000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10488345
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7432212
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9044000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25901000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30515000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
75935000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7425444
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2325226
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
793242
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.69
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8871328
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3756000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4604321
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2777000
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10488345
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9080820
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10488345
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7432212
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9044000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25901000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30515000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
75935000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40962116
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40962116
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1648608
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57851110
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43864838
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57564413
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42610724
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.85
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.78
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40962116
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57851110
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43864838
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57564413
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40962116
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1648608
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57851110
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43864838
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42610724
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.78

Files In Submission

Name View Source Status
0001558370-24-015304-index-headers.html Edgar Link pending
0001558370-24-015304-index.html Edgar Link pending
0001558370-24-015304.txt Edgar Link pending
0001558370-24-015304-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20240930.xsd Edgar Link pending
vygr-20240930x10q.htm Edgar Link pending
vygr-20240930xex10d1.htm Edgar Link pending
vygr-20240930xex10d2.htm Edgar Link pending
vygr-20240930xex31d1.htm Edgar Link pending
vygr-20240930xex31d2.htm Edgar Link pending
vygr-20240930xex32d1.htm Edgar Link pending
vygr-20240930_cal.xml Edgar Link unprocessable
vygr-20240930_def.xml Edgar Link unprocessable
vygr-20240930_lab.xml Edgar Link unprocessable
vygr-20240930_pre.xml Edgar Link unprocessable
vygr-20240930x10q_htm.xml Edgar Link completed
0001558370-24-015304-index-headers.html Edgar Link pending
0001558370-24-015304-index.html Edgar Link pending
0001558370-24-015304.txt Edgar Link pending
0001558370-24-015304-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vygr-20240930.xsd Edgar Link pending
vygr-20240930x10q.htm Edgar Link pending
vygr-20240930xex10d1.htm Edgar Link pending
vygr-20240930xex10d2.htm Edgar Link pending
vygr-20240930xex31d1.htm Edgar Link pending
vygr-20240930xex31d2.htm Edgar Link pending
vygr-20240930xex32d1.htm Edgar Link pending
vygr-20240930_def.xml Edgar Link unprocessable
vygr-20240930_lab.xml Edgar Link unprocessable
vygr-20240930_pre.xml Edgar Link unprocessable
vygr-20240930x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
vygr-20240930_cal.xml Edgar Link unprocessable